WELL Health Technologies Corp., a digital health company focused on tech-enabling healthcare providers, and HEALWELL AI Inc., a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the expansion of their multi-year strategic alliance agreement that allows WELL and HEALWELL to launch and manage clinical trial sites at WELL clinic locations across Canada. Leveraging the country’s largest network of primary and specialty care clinics, with over 180 clinics and thousands of healthcare practitioners, HEALWELL and WELL will collaborate to expand clinical trial access to more patients than ever before. By combining their strengths in healthcare infrastructure and AI technology, WELL and HEALWELL aim to transform the clinical research landscape.
This partnership allows HEALWELL AI to offer an end-to-end vertically integrated service, from patient recruitment to trial execution and data analysis for clinical research. By including WELL Health Diagnostic Centres (WHDC) and its robust specialty care patient roster, including cardiology, radiology, sleep medicine and endocrinology, the partnership can leverage valuable patient data to enhance research, particularly in cardiovascular disease and its co-morbidities, where pharmaceutical interest is significant. For WELL, hosting trials within its clinics will transform them into hubs of innovation, directly benefitting patients by bringing experimental treatments to local sites and improving accessibility. Leveraging HEALWELL’s Contract Research Organization (CRO) capabilities alongside WELL’s clinic infrastructure positions the partnership as a formidable player in AI-driven clinical trials, fostering the potential for new revenue.
Dr. Michael Frankel, Chief Medical Officer of WELL, commented, “Launching and managing clinical trial sites at WELL’s clinic locations across Canada is a powerful and transformational strategic initiative. This initiative will allow WELL and HEALWELL AI to capitalize on their combined strengths in healthcare infrastructure and AI technology, potentially transforming the landscape for clinical research.”
Also Read: RedMane Names Marc Campbell COO
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “Patient identification and recruitment for clinical trials has become an increasingly complex challenge in the global healthcare and life science sectors. Success hinges not only on identifying patients but also on effectively recruiting them and managing their participation – steps that lead to improved outcomes for patients, practitioners and the healthcare system as a whole. Through our established late stage CRO, Canadian Phase Onward, HEALWELL has already made significant strides in accelerating the recruitment process, but the growing network of WELL clinics is an opportunity for us to execute our plans at scale. Ultimately, this service will be a benefit to doctors, healthcare practitioners and patients alike while reducing the cost of clinical trials and shortening their timelines.”
Some strategic benefits of the partnership include:
- Increased Access to Clinical Trials: With WELL’s extensive and growing network of over 180 primary and specialty clinics nationwide, patients across diverse Canadian regions will have more convenient access to clinical trials. This expansive reach supports recruitment for a wide array of clinical trial programs, from common therapeutic areas to highly specialized conditions. HEALWELL focuses on recruiting niche patient populations, including those with rare diseases, specific genetic profiles, or unique demographic backgrounds. This focus improves the feasibility and inclusivity of trials, enabling sponsors to explore treatments for unmet medical needs. As a result, trials can achieve greater patient participation and gather more representative data, ultimately strengthening the value and relevance of clinical research findings.
- Enhanced Efficiency with AI-Driven Solutions: HEALWELL’s focus on advanced AI and data science is expected to streamline trial processes, from patient recruitment to data analysis. AI-driven tools also help identify eligible participants, predict outcomes, and reduce trial duration by automating data collection and analysis, making the process more efficient and cost-effective.
- Strengthened Position in the Healthcare Innovation Market: By establishing a unique niche in AI-enhanced clinical trials, WELL and HEALWELL position themselves as leaders in the emerging space of digital healthcare solutions for research. These efforts will enhance partnerships with pharmaceutical companies and other research institutions seeking to leverage AI for trial optimizations, contributing to financial growth and technological development.
- Data-Driven Insights for Future Healthcare Innovations: Operating clinical trials at scale will generate valuable real-world data that can inform future healthcare innovations. These insights can support HEALWELL AI‘s goal to enhance disease detection and preventative care tools, creating a cycle of continuous improvement that benefits both clinical outcomes and business objectives.
Source: PRNewswire